Astrana Health (ASTH) vs InnovAge (INNV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
InnovAge (INNV) has outperformed Astrana Health (ASTH) over the past year, gaining 53.2% versus a gain of 23.4%. Over five years, INNV leads with a +41.7% price change compared with -47.5% for ASTH. Astrana Health is the larger company by market cap ($1.86 billion vs $1.24 billion), about 1.5 times the size.
On valuation, Astrana Health trades at a lower forward P/E (10.3x vs 18.2x for InnovAge). Astrana Health converts more of its revenue into profit, with a net margin of 0.7% versus -0.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | INNV |
|---|---|---|
| Share price | $37.55 | $9.10 |
| Market cap | $1.86B | $1.24B |
| 1-day change | +4.68% | -0.11% |
| YTD return | +51.35% | +75.34% |
| 1-year return | +23.44% | +53.20% |
| 5-year return | -47.48% | +41.74% |
| P/E ratio (TTM) | 45.24 | — |
| Forward P/E | 10.33 | 18.20 |
| EPS (TTM) | $0.83 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.18B | $989.71M |
| Revenue growth (YoY) | +56.39% | +15.93% |
| Net income (latest FY) | $22.49M | $-2.54M |
| Gross margin | 10.73% | 23.01% |
| Operating margin | 2.47% | 0.26% |
| Net margin | 0.71% | -0.26% |
| 52-week high | $51.60 | $12.64 |
| 52-week low | $18.08 | $3.94 |
| Distance from 52-week high | -27.23% | -28.01% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +37.60% | +31.87% |
| Average volume | 460.33K | 460.49K |
| Shares outstanding | 49.60M | 136.45M |
| Employees | 3,000 | 2,500 |
| Sector | Consumer Discretionary | Health Care |
| Industry | Professional Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INNV has outperformed ASTH by 29.8 percentage points over the past year.
- Astrana Health grew revenue faster in its latest fiscal year (+56.39% vs +15.93%).
- The two companies sit in different sectors: Astrana Health in Consumer Discretionary and InnovAge in Health Care.
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About InnovAge
INNV stock →InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors.
Health Care · Medical/Nursing Services · 2,500 employees
ASTH vs INNV FAQ
Which is bigger, Astrana Health or InnovAge?
Astrana Health (ASTH) is larger, with a market capitalization of $1.86B compared with $1.24B for InnovAge (INNV).
Which stock has performed better over the past year, ASTH or INNV?
INNV returned +53.20% over the past 12 months, compared with +23.44% for ASTH (price return, excluding dividends). Past performance does not predict future results.
Are Astrana Health and InnovAge in the same industry?
No. Astrana Health is in the Consumer Discretionary sector, while InnovAge is in Health Care.